BioVie Inc. (BIVI)
| Market Cap | 11.46M -49.5% |
| Revenue (ttm) | n/a |
| Net Income | -19.96M |
| EPS | -3.49 |
| Shares Out | 7.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,469 |
| Open | 1.470 |
| Previous Close | 1.520 |
| Day's Range | 1.470 - 1.530 |
| 52-Week Range | 1.060 - 12.100 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 11, 2026 |
About BIVI
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly... [Read more]
Financial Performance
Financial StatementsNews
BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease
BioVie (BIVI) announced that the last patient evaluation visit has been completed for the company’s SUNRISE-PD Phase 2 trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease...
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease
Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026 Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026
BioVie Quarterly report: Q3 2026
BioVie has published its Q3 2026 quarterly earnings report on May 11, 2026.
BioVie Transcript: KOL event
The event highlighted the central role of metabolic dysregulation and inflammation in neurodegenerative diseases, with bezisterim positioned as a novel anti-inflammatory agent targeting both motor and non-motor symptoms in Parkinson's. Key biomarkers include DNA methylation and biological age, with trial results expected by end of Q2 or early Q3.
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...
BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
The presentation highlighted imminent clinical data readouts for bezisterim in Parkinson's and long COVID, both representing multi-billion dollar U.S. market opportunities. The company is advancing a spin-off for its liver disease asset and is considered undervalued with strong insider ownership.
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...
BioVie Slides: Corporate presentation
BioVie has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
BioVie Transcript: Status update
Bezisterim is advancing in phase II trials for Parkinson's and long COVID, with key data readouts expected in Q2 and late summer 2024. BIV201 for ascites is preparing for phase III after strong phase II results. Strategic focus is on Parkinson's, with long COVID as a potential priority if results and FDA guidance are favorable.
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right...
BioVie Quarterly report: Q2 2026
BioVie has published its Q2 2026 quarterly earnings report on February 6, 2026.
BioVie completes enrollment in Phase 2 SUNRISE-PD trial
BioVie (BIVI) completed enrollment of 60 patients in its Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in individuals with early-st...
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9
CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodeg...
BioVie Transcript: AGM 2025
The meeting established a quorum, elected six directors for a one-year term, ratified EisnerAmper, LLP as auditor for 2026, and approved an amendment to the 2019 Omnibus Equity Incentive Plan. All proposals passed with strong majority support.
BioVie Quarterly report: Q1 2026
BioVie has published its Q1 2026 quarterly earnings report on November 10, 2025.
BioVie Transcript: Investor Update
Multiple clinical trials are progressing, with key data readouts for Parkinson's, Long COVID, and ascites expected by mid-2026. Lead drug bezisterim targets TNF-alpha and shows promise in neurodegenerative and inflammatory conditions, while financial runway extends through 2026.
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...
BioVie Proxy statement: Proxy Filing
BioVie filed a proxy statement on September 25, 2025, providing details for shareholder voting and corporate governance matters.
BioVie price target adjusted to $12 from $6 at Brookline
Brookline adjusted the firm’s price target on BioVie (BIVI) to $12 from $6 and keeps a Buy rating on the shares. The firm cites the company’s recent 1-for-10 reverse stock…
BioVie Annual report: Q4 2025
BioVie has published its Q4 2025 annual report on August 15, 2025.
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue ...
Why Is BioVie Stock (BIVI) Down 50% Today?
BioVie stock was down on Friday after the company priced shares in a public offering.
BioVie 6M share Secondary priced at $2.00
The deal priced below last closing price of $2.91. ThinkEquity is acting as sole book running manager for the offering.
BioVie Inc. Announces Pricing of $12 Million Public Offering
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debi...